An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.
Cedars-Sinai published research in JAMA Cardiology this week on a algorithm it developed to detect atrial fibrillation in people not yet showing symptoms. The study found that the AI model does a good job of identifying hidden signals in common medical diagnostic testing and could help physicians better prevent strokes and other heart-related complications in people with atrial fibrillation.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
With so much supporting data and real-world success, it is time for catheter ablation to become a routine treatment option for patients suffering from arrhythmias.
This is the second Fast Track designation Anthos has received for abelacimab in less than two months. The therapeutic is also the first Factor XI inhibitor to start enrolling patients in Phase 3 trials.
By placing the power to detect atrial fibrillation into the hands of 6 billion global smartphone users, validation of further physiological parameters will be expedited and the subsequent adoption of this technology into DTx will enable the low-cost tools required to remove barriers to care and improve heart health across the globe.
Th FDA granted another 510(k) clearance to iRhythm Technologies for its AI-powered software system designed for use with Verily’s irregular pulse tracking watch. The clearance is for an algorithm that categorizes patients’ AFib by analyzing how much of it they experience over time.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
An infographic illustrates how Medtronic’s AccuRhythm AI suppresses false alerts while maintaining sensitivity.
The key challenge for primary care is the current lack of means for population-wide screening as this significantly lowers our ability to catch the condition early in patients within this golden window.
Pulsed Field Ablation can be used in several different ways, but its most valuable benefits are best illustrated through catheter ablation of atrial fibrillation (AF), and it’s important for it to be put in context.
The results, shared at AHA 2021, found that a third of adults who used an ECG patch after getting a heart rhythm notification from their Fitbit had atrial fibrillation. However, the study faced some challenges with adherence, as many patients who got a notification did not follow up.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A study published in Circulation showed that the Apple Watch’s ECG detected some arrhythmias other than atrial fibrillation. The device is currently cleared to take ECGs and general irregular pulse alerts, which could indicate potential cases of atrial fibrillation.
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
The digital health company filed a complaint with the Federal Trade Commission last week, seeking a ban on the import of the Apple Watch. AliveCor cited copyright violations related to Apple’s ECG feature as the reason for seeking the ban.
The wearables maker received 510(k) clearance for an electrocardiogram app used to assess heart rhythm for atrial fibrillation.